| (Values in U.S. Thousands) | Mar, 2016 | Dec, 2015 | Sep, 2015 | Jun, 2015 | Mar, 2015 |
| Sales | -9,999,000 | 660 | 70 | 80 | 190 |
| Sales Growth | -1,515,097.70% | +842.85% | -12.50% | -57.89% | -83.90% |
| Net Income | -9,999,000 | -10,110 | -21,560 | -11,330 | -12,180 |
| Net Income Growth | -98,802.09% | +53.11% | -90.29% | +6.98% | -14.47% |
Discovery Labs Inc (DSCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Discovery Laboratories, Inc., formerly known as Ansan Pharmaceuticals, Inc., is a development-stage pharmaceutical company that focuses on developing compounds to treat respiratory diseases that affect the ability of the lungs to absorb oxygen. It is initially developing its lead product candidate, Surfaxin, for use by newborn infants to treat two respiratory conditions in critical care units of hospitals. The second compound under development is SuperVent, which is intended to treat airway diseases such as cystic fibrosis (CF) and chronic bronchitis.